Enlicitide Decanoate

Merck's enlicitide decanoate (MK-0616) is the first oral PCSK9 inhibitor to clear FDA review, approved on July 16, 2026 for LDL cholesterol reduction under NDA 220848 [1]. The remaining pipeline story lives in CORALreef Outcomes (NCT06008756), the Phase 3 cardiovascular outcomes trial asking whether a daily pill can cut heart attacks and strokes in high-risk hypercholesterolemia patients on top of standard statin therapy [2]. Every existing PCSK9 drug is an injectable: Amgen's Repatha and Regeneron/Sanofi's Praluent are biweekly antibody shots, Novartis's Leqvio is a twice-yearly siRNA. Enlicitide is a macrocyclic peptide engineered to survive gut digestion and be absorbed orally, a rare feat for a peptide drug [3]. If CORALreef Outcomes shows MACE reduction, Merck has a mass-market cardiovascular product that goes head-to-head with statins on convenience while adding a mechanism proven to bend the risk curve. Merck reported roughly $65 billion in total revenue in 2025 and clearly views this asset as a legacy franchise successor to its cardiometabolic and vaccine businesses [4].

The compound is no longer purely investigational. FDA approved enlicitide decanoate on July 16, 2026 for adults with primary hypercholesterolemia (NDA 220848, sponsor MSD) [1]. That approval rested on a stack of completed Phase 3 lipid trials: CORALreef Lipids (NCT05952856, n=2,912) [5], a placebo-controlled trial published in NEJM in 2026 [6], a head-to-head against oral nonstatin therapies published in JACC [7], and a randomized trial in heterozygous familial hypercholesterolemia published in JAMA [8]. CORALreef Outcomes (NCT06008756) is the outstanding pipeline pillar, a long-term event-driven MACE trial run in collaboration with the TIMI Study Group under the TIMI 77 designation, with a registered primary completion date of November 2029 [2]. Enrollment target is approximately 14,500 participants. Supporting Phase 3 work continues in NCT07216482 (n=996, enlicitide plus rosuvastatin versus placebo, active but no longer recruiting) [9]. Line-extension programs are in earlier phases: a Phase 2 combination with Merck's MK-7262 for elevated Lp(a) (NCT07614984, n=750) [10] and a pediatric HeFH study (NCT07058077, n=153) [11]. No FDA breakthrough or priority review designations have been publicly disclosed for the outcomes indication.

PCSK9 is a protein made by the liver that acts like a garbage tag for LDL receptors. LDL receptors are the docks on liver cells that pull LDL cholesterol out of the bloodstream. When PCSK9 binds an LDL receptor, the receptor gets dragged inside the cell and destroyed instead of recycled, so fewer docks are available and LDL builds up in the blood [12]. Block PCSK9 and the docks stay on the surface, LDL gets cleared faster, and blood cholesterol falls. The target is one of the most genetically validated in cardiovascular medicine: people born with loss-of-function PCSK9 mutations have low lifelong LDL and dramatically reduced heart attack rates, while gain-of-function mutations cause severe familial hypercholesterolemia. Three approved PCSK9 drugs (evolocumab, alirocumab, inclisiran) have shown LDL reductions of 50 to 60 percent and, for the antibodies, hard cardiovascular event reduction in FOURIER and ODYSSEY OUTCOMES. Enlicitide takes the same mechanism and delivers it as a once-daily pill. The chemistry trick is a macrocyclic peptide, a ring-shaped short protein stabilized enough to survive stomach acid and be absorbed intact [3]. The 'decanoate' in the name refers to a decanoic acid (10-carbon fatty acid) ester attached to the peptide as a prodrug modification to further improve intestinal absorption and pharmacokinetics; the ester is cleaved in vivo to release the active peptide. Reported LDL reductions from Phase 3 pooling sit in the 57 to 65 percent range on top of statins, at or above the range achieved by the injectables [6][7].

CORALreef Outcomes (NCT06008756), also known as TIMI 77, is a Phase 3, randomized, double-blind, placebo-controlled cardiovascular outcomes trial in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease [2]. The primary endpoint is time to first occurrence of a five-component expanded MACE composite: coronary heart disease death, ischemic stroke, myocardial infarction, acute limb ischemia or major amputation, or urgent arterial revascularization. This is notably broader than the four-component composites used in FOURIER (Repatha) and ODYSSEY OUTCOMES (Praluent), because it explicitly captures peripheral artery disease events. That widens the outcomes net but also lowers the bar for accruing events, and it means direct cross-trial comparisons of hazard ratios need to be done carefully. The trial enrolled approximately 14,500 participants, smaller than FOURIER (n=27,564) or ODYSSEY OUTCOMES (n=18,924), which is a legitimate power question if event rates in intensively statin-treated patients turn out lower than modeled. Patients are randomized on top of maximally tolerated statin therapy, which is the appropriate comparator given that guidelines already mandate statins first-line. This is an event-driven trial rather than a fixed-duration study, meaning enrollment and follow-up continue until a pre-specified number of MACE events accrue. Design concerns are minimal: the endpoint is regulator-accepted, the comparator is honest, the mechanism has already been validated in outcomes trials for the injectable antibodies, and Merck plus the TIMI Study Group have run and reported large cardiovascular programs before. Registered primary completion is November 2029 [2].

Our model estimates a 44% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 57%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase and more secondary endpoints than usual; it is held back by weak or limited earlier-phase results and heavier-than-usual blinding. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the smallest bucket. LDL reduction has been demonstrated in four separate Phase 3 trials with reductions of 57 to 65 percent, and PCSK9 outcomes have already been won by two injectable antibodies. The real efficacy question is magnitude of MACE reduction on top of modern statin therapy, which could be modest in absolute event counts even if the relative risk reduction is real. The expanded five-component endpoint (including acute limb ischemia and major amputation) helps the trial capture events but makes hazard ratio interpretation less directly comparable to FOURIER and ODYSSEY OUTCOMES. Safety risk is contained but not zero. The PCSK9 class has a clean safety profile in the antibodies, but enlicitide is an oral peptide with different pharmacokinetics and different tissue exposure. Long-term exposure in millions of patients could surface signals not seen in trials, and GI intolerance is a known concern for oral peptides. Regulatory risk on CORALreef Outcomes is low given the design and the TIMI Study Group co-conduct. Commercial risk is where the story gets interesting. Statins are generic and cheap. Payers already push back hard on injectable PCSK9 drugs, and Repatha and Praluent both saw major price cuts. Inclisiran's twice-yearly dosing is a compliance argument enlicitide has to counter with pill convenience. Merck has not yet publicly disclosed a wholesale acquisition cost or payer strategy for the approved indication, and that pricing signal will be the near-term catalyst that decides whether enlicitide reaches broad primary prevention use or gets restricted to high-risk secondary prevention niches, capping the addressable market well below internal forecasts.

Signal, not noise. The approval on July 16, 2026 already de-risks the LDL claim and establishes commercial infrastructure. The pipeline value now sits almost entirely in CORALreef Outcomes (TIMI 77), which is a binary event on the biggest cardiovascular endpoint in medicine. A positive MACE readout converts enlicitide from a convenience play into a category-defining product, because no injectable competitor can match a daily pill on adherence, and adherence is where real-world LDL programs actually fail. The anchor date to circle is November 2029, the registered primary completion for NCT06008756 [2]. Any earlier interim analysis would need to be disclosed by Merck; there is no public basis to assume a specific 2027 or 2028 look. Watch three things. First, the Merck launch price and payer coverage decisions for the approved LDL indication, disclosed via Q3 or Q4 2026 earnings [4]. Second, the MK-7262 combination readout for elevated Lp(a) (NCT07614984) [10]. Lp(a) is a genetically-driven lipoprotein particle that current lipid drugs, including statins and PCSK9 inhibitors, do not reliably lower, and it is now recognized as an independent driver of residual cardiovascular risk. MK-7262 is Merck's investigational Lp(a)-lowering agent (a small interfering RNA targeting hepatic apolipoprotein(a) production), and a Lp(a) plus LDL combo would extend the franchise into territory no competitor has locked down. Third, any TIMI 77 event-accrual updates presented at American Heart Association Scientific Sessions or American College of Cardiology meetings, which are the standard venues for interim outcomes trial commentary.